Utilizing this model in ER+ breast cancer patients could help to identify which patients are likely to favorably respond to CDK4/6 inhibition and which patients will probably have intrinsic resistance, and therefore should take a different course of treatment. The gene discussed is CDK4; the disease is breast cancer.